SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lundstam Sven 1944)
 

Sökning: WFRF:(Lundstam Sven 1944) > (2020-2024) > Survival advantage ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005833naa a2200673 4500
001oai:gup.ub.gu.se/297106
003SwePub
008240528s2020 | |||||||||||000 ||eng|
009oai:DiVA.org:oru-85509
009oai:DiVA.org:umu-175380
009oai:prod.swepub.kib.ki.se:144621477
0247 a https://gup.ub.gu.se/publication/2971062 URI
0247 a https://doi.org/10.1080/21681805.2020.18158332 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-855092 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1753802 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1446214772 URI
040 a (SwePub)gud (SwePub)orud (SwePub)umud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Ljungberg, Börje,c Professor,d 1949-u Umeå universitet,Urologi och andrologi4 aut0 (Swepub:umu)bolj0001
2451 0a Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting
264 c 2020-09-08
264 1b Medical Journals Sweden AB,c 2020
520 a Background Recently, the CARMENA and SURTIME studies, suggested that upfront cytoreductive nephrectomy (CN) should be abandoned for patients with intermediate and high-risk metastatic renal cell carcinoma (mRCC). However, CN remains an indication in low-risk and when immediate systemic treatment is not required. The aim was to evaluate the long-term overall survival (OS) in patients with primary mRCC, based on the first line treatment. Methods There were 1483 patients with primary mRCC in the National Kidney Cancer Registry from 2005 to 2013. Data on primary treatment, TNM stage, RCC type, tumor size, patient age and sex were extracted. Survival time was calculated from time of diagnosis to time of death or until July 2019. Mann-Whitney U and Chi-square tests, the Kaplan-Meyer method and Cox regression analyses were used. Results Patients primary treated with CN had a significantly longer OS (p < .001) than patients primary treated with systemic therapy or palliation. In a Cox regression multivariate analysis, the hazard ratio for CN compared with no CN was 1.600, 95%Ci (1.492 - 1.691),p < .001. Also occurrence of lymph node metastases, T-stage, patients age and year of diagnosis, remained as independent predictors of OS. Conclusion Patients primary treated with CN survived significantly longer than patients primary treated with systemic therapy or palliation, in all age groups. CN was an important first-line treatment option in mRCC patients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a cytoreductive nephrectomy
653 a metastatic renal cell carcinoma
653 a renal cell
653 a carcinoma
653 a systemic therapy
653 a targeted therapy
653 a planned nephrectomy
653 a cancer
653 a Urology & Nephrology
653 a Cytoreductive nephrectomy
7001 a Sundqvist, Pernilla,d 1973-u Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Urology4 aut0 (Swepub:oru)pst
7001 a Lindblad, Per,d 1953-u Örebro universitet,Institutionen för medicinska vetenskaper,Department of Urology4 aut0 (Swepub:oru)pld
7001 a Kjellman, A.u Karolinska Institutet4 aut
7001 a Thorstenson, A.u Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden4 aut
7001 a Hellström, Mikael,d 1950u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för radiologi,Institute of Clinical Sciences, Department of Radiology,Department of Radiology, Sahlgrenska Academy, Gothenburg University, and Sahlgrenska University Hospital, Gothenburg, Sweden4 aut0 (Swepub:gu)xhelmi
7001 a Kröger Dahlin, Britt-Ingeru Umeå universitet,Urologi och andrologi4 aut0 (Swepub:umu)dinbrr00
7001 a Thomasson, Marcusu Umeå universitet,Onkologi4 aut0 (Swepub:umu)math0013
7001 a Harmenberg, U.u Department of Oncology, Karolinska University Hospital/Karolinska Institute, Stockholm, Sweden4 aut
7001 a Lundstam, Sven,d 1944u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology,Department of Urology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden4 aut0 (Swepub:gu)xlusvl
7102 a Umeå universitetb Urologi och andrologi4 org
7730 t Scandinavian Journal of Urologyd : Medical Journals Sweden ABg 54:6, s. 487-492q 54:6<487-492x 2168-1805x 2168-1813
8564 u https://www.tandfonline.com/doi/pdf/10.1080/21681805.2020.1815833?needAccess=true
8564 u https://doi.org/10.1080/21681805.2020.1815833y Fulltext
8564 u https://umu.diva-portal.org/smash/get/diva2:1471396/FULLTEXT02.pdfx primaryx Raw objecty fulltext:print
8564 8u https://gup.ub.gu.se/publication/297106
8564 8u https://doi.org/10.1080/21681805.2020.1815833
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-85509
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-175380
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:144621477

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy